Replies to post #1923 on Biotech Values

[rstor1]

+++Overlapping phase-2 and phase-3 trials --this is a very positive development!+++

I have mixed feelings about that. Are they so confident of the dosing schedule that they don't need the PII data? Seems like a risky way of going forward, and I can't help but think that it is motivated by non-science considerations - like forcing the hand of prospective partners.

Bob

[rkcrules2001]

SPA -- ??

<<I can’t wait to see the trial-design details and the list of clinical sites>>

Any prediction about when an announcement of an SPA would be made? With the trial details? Or before, or later?

Finally some fun. It's been dull too long.